Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.

British Journal of Cancer
J H BaekW Yu

Abstract

The present study was conducted to evaluate the efficacy and safety of a combination regimen of capecitabine plus irinotecan in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received oral capecitabine 1000 mg m(-2) twice daily from day 1 to 14 and intravenous irinotecan 100 mg m(-2) on days 1 and 8, based on a 3-week cycle. Forty-one patients were enrolled in the current study, among whom 38 were assessable for efficacy and 40 assessable for toxicity. Three complete responses and 16 partial responses were confirmed, giving an overall response rate of 46.3%. At a median follow-up of 269 days, the median time to progression and overall survival were 5.1 and 8.6 months, respectively. Grade 3/4 neutropenia occurred in four patients and grade 3 febrile neutropenia was observed in two patients. Grade 3 diarrhoea and grade 2 hand-foot syndrome occurred in six patients and eight patients, respectively. The combination of capecitabine and irinotecan was found to be well tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as one of first-line treatment options for advanced gastric cancer.

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Feb 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusP O Sjödén
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L BlumT Griffin
Aug 17, 1999·International Journal of Cancer. Journal International Du Cancer·P PisaniJ Ferlay
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N BokuI Hyodo
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A FalconeP Conte
Nov 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T W KimJ S Lee
Apr 17, 2003·Oncology·Wasaburo KoizumiUNKNOWN Clinical Study Group of Capecitabine
Jun 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Bugat
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TewesU Vanhoefer
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M M BornerUNKNOWN Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
Apr 23, 2005·The Cochrane Database of Systematic Reviews·A D WagnerW E Fleig
Jun 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D W ReaC J A Punt
Oct 1, 2003·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Myung Ju AhnHeung Woo Lee

❮ Previous
Next ❯

Citations

May 17, 2014·World Journal of Gastroenterology : WJG·Byung Woog KangWansik Yu
Apr 15, 2008·Future Oncology·Jae-Lyun Lee, Yoon-Koo Kang
Apr 24, 2007·Acta Oncologica·Theodoros FoukakisPehr A Lind
Oct 17, 2015·Expert Review of Gastroenterology & Hepatology·Tae-Yong KimYung-Jue Bang
Mar 3, 2009·Pharmacotherapy·Pasquale ComellaEnrica Menditto
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Alicia OkinesDavid Cunningham
Feb 3, 2016·F1000Research·Martin L AshdownBrendon J Coventry
Nov 17, 2006·Pharmacogenetics and Genomics·Susanne B HagaWylie Burke
Apr 13, 2007·Cancer Chemotherapy and Pharmacology·Jong Gwang KimYoon-Koo Kang
Aug 5, 2011·Drugs·Jaclyn YoongTrevor Leong
May 23, 2012·Investigational New Drugs·Nilesh A PatankarMarcel B Bally
Mar 20, 2015·Cell Biology International·Sara SalatinAhmad Yari Khosroushahi
Nov 26, 2011·Expert Review of Anticancer Therapy·Yung-Jue Bang
Apr 20, 2010·Expert Review of Anticancer Therapy·Fadi S FarhatMarwan G Ghosn

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.